{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T12:23:54Z","timestamp":1771849434554,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.clon.2013.11.022","type":"journal-article","created":{"date-parts":[[2013,12,7]],"date-time":"2013-12-07T23:00:16Z","timestamp":1386457216000},"page":"110-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Bortezomib in Multiple Myeloma: A Practice Guideline"],"prefix":"10.1016","volume":"26","author":[{"given":"C.T.","family":"Kouroukis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.G.","family":"Baldassarre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.E.","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Imrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.E.","family":"Reece","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.C.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2013.11.022_bib1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1517\/13543780903002074","article-title":"Clinical development of novel proteasome inhibitors for cancer treatment","volume":"18","author":"Yang","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clon.2013.11.022_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3747\/co.v13i5.106","article-title":"Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline","volume":"13","author":"Reece","year":"2006","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clon.2013.11.022_bib3","series-title":"Bortezomib approved in Canada as first-line treatment of multiple myeloma","author":"Anonymous","year":"2008"},{"key":"10.1016\/j.clon.2013.11.022_bib4","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3109\/10428194.2010.487959","article-title":"Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches","volume":"51","author":"Engelhardt","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clon.2013.11.022_bib5","series-title":"NCCN clinical practice guidelines in oncology (NCCN Guidelines\u2122): multiple myeloma","year":"2011"},{"key":"10.1016\/j.clon.2013.11.022_bib6","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2009.122","article-title":"International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation","volume":"23","author":"Palumbo","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clon.2013.11.022_bib7","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1200\/JCO.1995.13.2.502","article-title":"The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation","volume":"13","author":"Browman","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.11.022_bib8","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2013.11.022_bib9","doi-asserted-by":"crossref","first-page":"A650","DOI":"10.1182\/blood.V112.11.650.650","article-title":"Updated follow-up\u00a0and results of subsequent therapy in the phase III VISTA\u00a0trial:\u00a0bortezomib plus melphalan-prednisone versus melphalan-prednisone in newly diagnosed multiple myeloma","volume":"112","author":"San Miguel","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clon.2013.11.022_bib10","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.11.022_bib11","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.11.022_bib12","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2013.11.022_bib13","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clon.2013.11.022_bib14","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/blood.V118.21.478.478","article-title":"Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, phase 3b UPFRONT study","volume":"118","author":"Niesvizky","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clon.2013.11.022_bib15","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.11.022_bib16","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2013.11.022_bib17","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1002\/cncr.26517","article-title":"A\u00a0randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid","volume":"118","author":"Sharma","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2013.11.022_bib18","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clon.2013.11.022_bib19","article-title":"A\u00a0phase III PETHEMA\/GEM randomised trial of posttransplant maintenance in multiple myeloma: superiority of bortezomib","volume":"47","author":"Rosinol","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clon.2013.11.022_bib20","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.11.022_bib21","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2013.11.022_bib22","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clon.2013.11.022_bib23","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.clon.2013.11.022_bib24","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1158\/1078-0432.CCR-10-1662","article-title":"A\u00a0phase I\/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study","volume":"16","author":"Lonial","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2013.11.022_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00280-010-1283-3","article-title":"Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma","volume":"67","author":"Reece","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clon.2013.11.022_bib26","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1600-0609.2012.01775.x","article-title":"Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study","volume":"88","author":"Hjorth","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clon.2013.11.022_bib27","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1200\/JCO.2011.37.4918","volume":"30","author":"Garderet","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.11.022_bib28","doi-asserted-by":"crossref","first-page":"8018","DOI":"10.1200\/jco.2012.30.15_suppl.8018","article-title":"Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed\/refractory multiple myeloma","volume":"30","author":"Orlowski","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.11.022_bib29","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.11.022_bib30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2013.11.022_bib31","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2141.2007.06585.x","article-title":"Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma","volume":"137","author":"Richardson","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clon.2013.11.022_bib32","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/sj.leu.2405087","article-title":"Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study","volume":"22","author":"San-Miguel","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clon.2013.11.022_bib33","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/cncr.23326","article-title":"Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide\/lenalidomide therapy","volume":"112","author":"Sonneveld","year":"2008","journal-title":"Cancer"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655513004639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655513004639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:39:14Z","timestamp":1760542754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655513004639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0936655513004639"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2013.11.022","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bortezomib in Multiple Myeloma: A Practice Guideline","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2013.11.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}